Biomarker Development for Muscular Dystrophies
NCT05019625
This study is recruiting at 4 US sites in 3 states, according to its ClinicalTrials.gov record last updated .
Summary
Current methods of measuring the response to new treatments for muscular dystrophies involve the examination of small pieces of muscle tissue called biopsies. The investigators are interested in finding less invasive methods that reduce the need for muscle biopsies. The purpose of this research is to learn about the possibility of detecting and measuring the activity and severity of muscular dystrophies by examining a urine sample and a blood sample, and some muscles in the arms and legs using tests called ultrasound and electrical impedance myography; both tests are painless and non-invasive.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Myotonic Dystrophy
- Duchenne Muscular Dystrophy
- Becker Muscular Dystrophy
- Facioscapulohumeral Muscular Dystrophy
Eligibility basics and study details
- Study type
- Observational
- Phase
- Not applicable
- Ages
- 5 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- Massachusetts General Hospital
- Last updated on ClinicalTrials.gov
- November 24, 2025
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Massachusetts · 2
- Brigham and Women's Hospital · Boston, MA
- Massachusetts General Hospital · Boston, MA
North Carolina · 1
- Wake Forest University · Winston-Salem, NC
Pennsylvania · 1
- University of Pittsburgh · Pittsburgh, PA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.